ABUS earnings date and last-quarter result: last quarter beat, P/E 5.19. Updated 2026-07-23.
Arbutus Biopharma (ABUS) Research Hub
Arbutus Biopharma (ABUS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 4.2 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 5.19, market cap 0.86B. This hub links to the full technical, earnings and options research available for ABUS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.2 USD (0.00%) |
| 52-week range | 4.05 USD – 5.45 USD |
| Trend regime | Range |
| 14-day RSI | 36 (Bearish) |
| Trailing P/E | 5.19 |
| Market cap | 0.86B |
| Dividend yield | 0.00% |
Available research for ABUS
Covered Call on ABUS: how it works, illustrative setup around the real 4.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ABUS: how it works, illustrative setup around the real 4.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ABUS: how it works, illustrative setup around the real 4.2 USD price, max profit/loss, breakeven and when to use it. Educational.
ABUS technical analysis: range, last 4.2 USD, RSI 36, 52w range 4.05 USD–5.45 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ABUS in?
Arbutus Biopharma (ABUS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ABUS in an uptrend or downtrend?
As of 2026-10-26, ABUS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ABUS's trailing P/E ratio?
ABUS's trailing P/E is 5.19, with a market cap of 0.86B. See the earnings research page for full valuation detail.